newsfilter
← Latest News
GlobeNewswire·

Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences

NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds managed by Blackstone Life